Atopic Dermatitis
Conditions
Brief summary
Spaced phototherapy sessions during winter as add-on therapy in combination with vitamin D supplementation or not, could be beneficial to improve disease LTC in AD patients
Detailed description
The major therapeutic challenge in patient with Atopic Dermatitis is long-term control of disease activity (LTC), for which the current TAT-based pro-active strategy does not meet all the needs. Phototherapy is a good candidate: it is widely used as a second-line treatment in AD with demonstrated efficacy. However, only short-term control has been evaluated; and only 2-3 times a week intensive schedules have been tested and are used in current practice. A novel phototherapy regimen would be required for disease LTC, allowing a trade-off between disease control, UV-induced risks, and patient adherence. Vitamin D supplementation is another good candidate: several studies have shown lower serum levels of vitamin D to be correlated with more severe AD; and three short-term, low-power low-quality, placebo-controlled randomised trials testing vitamin D supplementation yielded conflicting results, leaving its therapeutic efficacy undecided for short-term control, and unknown for LTC.
Interventions
DRUGCholecalciferol
Sponsors
Rennes University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with atopic dermatitis (Hanifin and Rajka criteria), * Aged 15 years or more, * With \> 2 years of disease evolution, * With moderate-to-severe disease (IGA \> 2), * Patients that have received TAT for at least 12 weeks and have symptoms requiring an increase in therapy, * Seasonality in disease severity (based on a questionnaire assessing disease improvement during summer), * Easy access to a phototherapy cabin (widely implanted in primary care dermatology private practice in France), * Effective contraception to be used at least 30 days before initiation of treatment, during treatment and 29 weeks after last administration for women of reproductive age, * Written informed consent of the patient * For patients aged between 15 and 18, written informed consent of the parents and of the teenager.
Exclusion criteria
* Any cause of contra-indication for vitamin D supplementation: flare of granulomatosis, primary hyperparathyroidism, * Clinical suspicion of hypercalciuria, * Indication to a systemic immunosuppressant in the next 2 years, * Atopic dermatitis known to be aggravated by UV exposure, * Any contra-indication for artificial or solar exposure including: genetic diseases with a predisposition to skin cancer, any history of personal skin cancer (melanoma, squamous cell skin cancer, basal cell skin cancer), lupus, dermatomyositis, any other photosensitizing skin disease, photosensitizing medication (see appendix 2), * More than 100 previous phototherapy sessions in lifetime, * Pregnancy or breastfeeding, * Persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hierarchical criterion based on repeated measures of PO-SCORAD severity score | 2 years | Measurement of PO-SCORAD score |
| Hierarchical criterion based on cumulative consumption of topical anti-inflammatory treatments (collected tubes) during winter | 2 years | Measurement of cumulative consumption of topical anti-inflammatory treatments |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of serum Vitamin D (25-(OH)-vitamin D) | 2 years | — |
| Measurement of total IgE serum | 2 years | — |
| Assessment of desease severity | 2 years | Assessment of desease severity by EASI score |
| Assessment of inter-visit cumulative consumption of topical anti-inflammatory treatments | 2 years | — |
| Assessment of patient satisfaction | 2 years | — |
| Assessement of number of weeks of well-controlled atopic dermatitis | 2 years | — |
| Assessment of the quality of life | 2 years | Assessment of the quality of life by DLQI score |
Countries
France
Outcome results
None listed